Biotech executives are beginning to publicly oppose President Trump’s proposed most-favored-nation (MFN) drug pricing policy as Congress considers whether to codify it. The policy would tie U.S. drug prices to the lowest prices paid in other wealthy countries. Leaders of several midsized biotech firms warn the approach could discourage investment and make it harder to raise capital for new therapies. The newly formed Midsized Biotech Alliance of America argues that smaller biotech companies are more vulnerable to government price-setting than large pharmaceutical firms with diversified portfolios. The pushback comes as Republican lawmakers weigh whether to advance legislation making the policy permanent.

Source: National Association of Benefits and Insurance Professionals